| Name | Title | Contact Details |
|---|
Biorem is a pioneer environmental biotechnology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). We offer a selection of products that can be tailored to suit application specific requirements. Biorem ensures optimized long-term performance on every application by custom-designing the solution to meet the individual needs of our clients. With sales and manufacturing offices across the continents, dedicated research facilities, analytical and microbial laboratories, worldwide sales representative network, and a dedicated service division, Biorem has the resources available to ensure that your project is handled promptly and professionally from conception to completion. With the largest installation base of it’s kind in the world, continued extensive research efforts, and over 21 years of experience, Biorem not only offers state of the art technology-based products – but also peace of mind for municipalities, industrial companies and their surrounding communities.
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.